Shore Capital taps former McKesson exec to lead Reliant Infusion

CHICAGO – Tommy Pourmahram has been named CEO of Reliant Infusion, a provider of specialty infusion services and a portfolio company of Shore Capital Partners. He brings more than 20 years of health care leadership to the role, most recently in senior executive positions at McKesson's Oncology & Multispecialty Segment. "We are thrilled to welcome Tommy to Reliant Infusion," said AJ Gauthier, principal at Shore Capital Partners. "His depth of health care experience and proven leadership make him an outstanding fit for this business and this team. We are equally grateful to (Founder Brad Smith), who built Reliant Infusion into one of the largest independent omnichannel infusion providers and will remain a strategic leader and board member." At McKesson, Pourmahram held commercial and operating leadership roles that contributed directly to the Oncology & Multispecialty Segment’s growth and its position as a leader in the specialty market. His experience spans specialty health, drug infusion, oncology operations, specialty biosimilars, generic injectables, GPO and distribution, and health care technology. Over his career, he has had P&L responsibility for multibillion-dollar portfolios, including businesses representing more than $25 billion in annual revenue. Shore Capital Partners says the transition reflects a deliberate plan to prepare Reliant Infusion for its next phase of growth. "Tommy is the kind of leader we build our partnerships around," said Mike Cooper, co-founder at Shore Capital Partners. "He has led at scale in specialty care and knows how to grow a business without losing sight of the patient."

• Related: In 2025, Reliant Healthcare was recapitalized by Shore Capital Partners and merged with Care Fusion Rx.